Comparing the effects of providing clinicians and patients with the results of an objective measure of activity and attention (QbTest) versus usual care on diagnostic and treatment decision making in children and young people with ADHD

A randomised controlled trial comparing the effects of providing clinicians and patients with the results of an objective measure of activity and attention (QbTest) versus usual care on diagnostic and treatment decision making in children and young people with ADHD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11727351

Enrollment

178

Registered

2016-07-04

Start date

2014-08-08

Completion date

Unknown

Last updated

2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Mental Health, Primary sub-specialty: Learning disorders Mental and Behavioural Disorders Attention deficit hyperactivity disorder (ADHD)

Interventions

The study consists of two arms, QbOpen (QBO) whereby the patient and clinician have immediate access to the QbTest report which can be used to inform clinical decision making and QbBlind (QbB) whereby

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 6-17 years (maximum 17 years at time of consent, may turn 18 during the study) 2. Referred for ADHD assessment 3. Capable of providing written informed consent (over 16) 4. Parental consent (under 16)

Exclusion criteria

Exclusion criteria: 1. Non-fluent in English 2. Suspected moderate or severe learning disability 3. Previous or current diagnosis of ADHD

Design outcomes

Primary

Measure	Time frame
Number of clinic sessions until a confirmed correct diagnosis is achieved is measured using an appointment pro-forma from baseline to 6 months.	—

Secondary

Measure	Time frame
1. Time to diagnosis (in days) and the duration of visits (in minutes) are measured using an appointment pro-forma within 6-month time period 2. Clinician’s degree of confidence in their diagnostic decision is measured using a 6-point Likert scale (1 = definitely ADHD, 6 = definitely not ADHD) within a6 month time period 3. Stability in diagnosis is measured by asking clinicians to re-rate their diagnostic decision and confidence at 6 months 4. Diagnostic accuracy of QbTest by comparing diagnosis with diagnosis made through the ‘gold standard’ assessment (DAWBA) from baseline to 6 months 5. Quality of decision making is assessed through the side effects scale from baseline to 6 months 6. Treatment response is measured using the Strengths and Difficulties Questionnaire (SDQ), Children's Global Assessment Scale (CGAS) and the Swanson, Nolan and Pelham Teacher and Parent Rating Scale IV (SNAP-IV) at baseline, 3 and 6 months 7. Quality of life is measured using the EQ-5D-Y questionnaire at baseline, 3 and 6 months 8. Cost effectiveness of the QbTest is measured using the Client Service Receipt Inventory (CSRI) at baseline, 3 and 6 months 9. Opinions of the QbTest are measured using a specifically designed questionnaire or participant interviews at 6 months	—

Measure

Time frame

1. Time to diagnosis (in days) and the duration of visits (in minutes) are measured using an appointment pro-forma within 6-month time period 2. Clinician’s degree of confidence in their diagnostic decision is measured using a 6-point Likert scale (1 = definitely ADHD, 6 = definitely not ADHD) within a6 month time period 3. Stability in diagnosis is measured by asking clinicians to re-rate their diagnostic decision and confidence at 6 months 4. Diagnostic accuracy of QbTest by comparing diagnosis with diagnosis made through the ‘gold standard’ assessment (DAWBA) from baseline to 6 months 5. Quality of decision making is assessed through the side effects scale from baseline to 6 months 6. Treatment response is measured using the Strengths and Difficulties Questionnaire (SDQ), Children's Global Assessment Scale (CGAS) and the Swanson, Nolan and Pelham Teacher and Parent Rating Scale IV (SNAP-IV) at baseline, 3 and 6 months 7. Quality of life is measured using the EQ-5D-Y questionnaire at baseline, 3 and 6 months 8. Cost effectiveness of the QbTest is measured using the Client Service Receipt Inventory (CSRI) at baseline, 3 and 6 months 9. Opinions of the QbTest are measured using a specifically designed questionnaire or participant interviews at 6 months

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 11, 2026